The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Erythropoietin (EPO)-Global Market Insights and Sales Trends 2024
Synopsis
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.
In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml
The global Erythropoietin (EPO) market size is expected to reach US$ 13700 million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. The market is mainly driven by the significant applications of Erythropoietin (EPO) in various end use industries. The expanding demands from the Anemia, Kidney Disorders and Other,, are propelling Erythropoietin (EPO) market. Epoetin-alfa, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Darbepoetin-alfa segment is estimated at % CAGR for the next seven-year period.
The major players in global Erythropoietin market include Amgen, Johnson & Johnson, etc. The top 2 players occupy about 60% shares of the global market. North America is the main market, and occupies over 65% of the global market. Epoetin-alfa is the main type, with a share about 80%. Kidney Disorders is the key application, which holds a share over 40%.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Erythropoietin (EPO), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Erythropoietin (EPO) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Erythropoietin (EPO) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Erythropoietin (EPO) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Erythropoietin (EPO) covered in this report include Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon and LG Life Sciences, etc.
The global Erythropoietin (EPO) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Global Erythropoietin (EPO) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Erythropoietin (EPO) market, Segment by Type:
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Global Erythropoietin (EPO) market, by Application
Anemia
Kidney Disorders
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Erythropoietin (EPO) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Erythropoietin (EPO) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.
In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml
The global Erythropoietin (EPO) market size is expected to reach US$ 13700 million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. The market is mainly driven by the significant applications of Erythropoietin (EPO) in various end use industries. The expanding demands from the Anemia, Kidney Disorders and Other,, are propelling Erythropoietin (EPO) market. Epoetin-alfa, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Darbepoetin-alfa segment is estimated at % CAGR for the next seven-year period.
The major players in global Erythropoietin market include Amgen, Johnson & Johnson, etc. The top 2 players occupy about 60% shares of the global market. North America is the main market, and occupies over 65% of the global market. Epoetin-alfa is the main type, with a share about 80%. Kidney Disorders is the key application, which holds a share over 40%.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Erythropoietin (EPO), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Erythropoietin (EPO) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Erythropoietin (EPO) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Erythropoietin (EPO) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Erythropoietin (EPO) covered in this report include Amgen, Johnson & Johnson, Roche, Galenica, Emcure, Kyowa Hakko Kirin, 3SBio, Biocon and LG Life Sciences, etc.
The global Erythropoietin (EPO) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Global Erythropoietin (EPO) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Erythropoietin (EPO) market, Segment by Type:
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Global Erythropoietin (EPO) market, by Application
Anemia
Kidney Disorders
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Erythropoietin (EPO) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Erythropoietin (EPO) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Erythropoietin (EPO) Market Overview
1.1 Erythropoietin (EPO) Product Overview
1.2 Erythropoietin (EPO) Market Segment by Type
1.2.1 Epoetin-alfa
1.2.2 Darbepoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Others
1.3 Global Erythropoietin (EPO) Market Size by Type
1.3.1 Global Erythropoietin (EPO) Market Size Overview by Type (2018-2029)
1.3.2 Global Erythropoietin (EPO) Historic Market Size Review by Type (2018-2023)
1.3.3 Global Erythropoietin (EPO) Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Erythropoietin (EPO) Sales Breakdown by Type (2018-2023)
1.4.2 Europe Erythropoietin (EPO) Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Erythropoietin (EPO) Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Erythropoietin (EPO) Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Erythropoietin (EPO) Sales Breakdown by Type (2018-2023)
2 Global Erythropoietin (EPO) Market Competition by Company
2.1 Global Top Players by Erythropoietin (EPO) Sales (2018-2023)
2.2 Global Top Players by Erythropoietin (EPO) Revenue (2018-2023)
2.3 Global Top Players by Erythropoietin (EPO) Price (2018-2023)
2.4 Global Top Manufacturers Erythropoietin (EPO) Manufacturing Base Distribution, Sales Area, Product Type
2.5 Erythropoietin (EPO) Market Competitive Situation and Trends
2.5.1 Erythropoietin (EPO) Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Erythropoietin (EPO) Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Erythropoietin (EPO) as of 2022)
2.7 Date of Key Manufacturers Enter into Erythropoietin (EPO) Market
2.8 Key Manufacturers Erythropoietin (EPO) Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Erythropoietin (EPO) Status and Outlook by Region
3.1 Global Erythropoietin (EPO) Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Erythropoietin (EPO) Historic Market Size by Region
3.2.1 Global Erythropoietin (EPO) Sales in Volume by Region (2018-2023)
3.2.2 Global Erythropoietin (EPO) Sales in Value by Region (2018-2023)
3.2.3 Global Erythropoietin (EPO) Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Erythropoietin (EPO) Forecasted Market Size by Region
3.3.1 Global Erythropoietin (EPO) Sales in Volume by Region (2024-2029)
3.3.2 Global Erythropoietin (EPO) Sales in Value by Region (2024-2029)
3.3.3 Global Erythropoietin (EPO) Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Erythropoietin (EPO) by Application
4.1 Erythropoietin (EPO) Market Segment by Application
4.1.1 Anemia
4.1.2 Kidney Disorders
4.1.3 Other
4.2 Global Erythropoietin (EPO) Market Size by Application
4.2.1 Global Erythropoietin (EPO) Market Size Overview by Application (2018-2029)
4.2.2 Global Erythropoietin (EPO) Historic Market Size Review by Application (2018-2023)
4.2.3 Global Erythropoietin (EPO) Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Erythropoietin (EPO) Sales Breakdown by Application (2018-2023)
4.3.2 Europe Erythropoietin (EPO) Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Erythropoietin (EPO) Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Erythropoietin (EPO) Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Erythropoietin (EPO) Sales Breakdown by Application (2018-2023)
5 North America Erythropoietin (EPO) by Country
5.1 North America Erythropoietin (EPO) Historic Market Size by Country
5.1.1 North America Erythropoietin (EPO) Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Erythropoietin (EPO) Sales in Volume by Country (2018-2023)
5.1.3 North America Erythropoietin (EPO) Sales in Value by Country (2018-2023)
5.2 North America Erythropoietin (EPO) Forecasted Market Size by Country
5.2.1 North America Erythropoietin (EPO) Sales in Volume by Country (2024-2029)
5.2.2 North America Erythropoietin (EPO) Sales in Value by Country (2024-2029)
6 Europe Erythropoietin (EPO) by Country
6.1 Europe Erythropoietin (EPO) Historic Market Size by Country
6.1.1 Europe Erythropoietin (EPO) Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Erythropoietin (EPO) Sales in Volume by Country (2018-2023)
6.1.3 Europe Erythropoietin (EPO) Sales in Value by Country (2018-2023)
6.2 Europe Erythropoietin (EPO) Forecasted Market Size by Country
6.2.1 Europe Erythropoietin (EPO) Sales in Volume by Country (2024-2029)
6.2.2 Europe Erythropoietin (EPO) Sales in Value by Country (2024-2029)
7 Asia-Pacific Erythropoietin (EPO) by Region
7.1 Asia-Pacific Erythropoietin (EPO) Historic Market Size by Region
7.1.1 Asia-Pacific Erythropoietin (EPO) Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Erythropoietin (EPO) Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Erythropoietin (EPO) Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Erythropoietin (EPO) Forecasted Market Size by Region
7.2.1 Asia-Pacific Erythropoietin (EPO) Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Erythropoietin (EPO) Sales in Value by Region (2024-2029)
8 Latin America Erythropoietin (EPO) by Country
8.1 Latin America Erythropoietin (EPO) Historic Market Size by Country
8.1.1 Latin America Erythropoietin (EPO) Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Erythropoietin (EPO) Sales in Volume by Country (2018-2023)
8.1.3 Latin America Erythropoietin (EPO) Sales in Value by Country (2018-2023)
8.2 Latin America Erythropoietin (EPO) Forecasted Market Size by Country
8.2.1 Latin America Erythropoietin (EPO) Sales in Volume by Country (2024-2029)
8.2.2 Latin America Erythropoietin (EPO) Sales in Value by Country (2024-2029)
9 Middle East and Africa Erythropoietin (EPO) by Country
9.1 Middle East and Africa Erythropoietin (EPO) Historic Market Size by Country
9.1.1 Middle East and Africa Erythropoietin (EPO) Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Erythropoietin (EPO) Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Erythropoietin (EPO) Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Erythropoietin (EPO) Forecasted Market Size by Country
9.2.1 Middle East and Africa Erythropoietin (EPO) Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Erythropoietin (EPO) Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Amgen
10.1.1 Amgen Company Information
10.1.2 Amgen Introduction and Business Overview
10.1.3 Amgen Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Amgen Erythropoietin (EPO) Products Offered
10.1.5 Amgen Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Introduction and Business Overview
10.2.3 Johnson & Johnson Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Johnson & Johnson Erythropoietin (EPO) Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Roche
10.3.1 Roche Company Information
10.3.2 Roche Introduction and Business Overview
10.3.3 Roche Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Roche Erythropoietin (EPO) Products Offered
10.3.5 Roche Recent Development
10.4 Galenica
10.4.1 Galenica Company Information
10.4.2 Galenica Introduction and Business Overview
10.4.3 Galenica Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Galenica Erythropoietin (EPO) Products Offered
10.4.5 Galenica Recent Development
10.5 Emcure
10.5.1 Emcure Company Information
10.5.2 Emcure Introduction and Business Overview
10.5.3 Emcure Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Emcure Erythropoietin (EPO) Products Offered
10.5.5 Emcure Recent Development
10.6 Kyowa Hakko Kirin
10.6.1 Kyowa Hakko Kirin Company Information
10.6.2 Kyowa Hakko Kirin Introduction and Business Overview
10.6.3 Kyowa Hakko Kirin Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Kyowa Hakko Kirin Erythropoietin (EPO) Products Offered
10.6.5 Kyowa Hakko Kirin Recent Development
10.7 3SBio
10.7.1 3SBio Company Information
10.7.2 3SBio Introduction and Business Overview
10.7.3 3SBio Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.7.4 3SBio Erythropoietin (EPO) Products Offered
10.7.5 3SBio Recent Development
10.8 Biocon
10.8.1 Biocon Company Information
10.8.2 Biocon Introduction and Business Overview
10.8.3 Biocon Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Biocon Erythropoietin (EPO) Products Offered
10.8.5 Biocon Recent Development
10.9 LG Life Sciences
10.9.1 LG Life Sciences Company Information
10.9.2 LG Life Sciences Introduction and Business Overview
10.9.3 LG Life Sciences Erythropoietin (EPO) Sales, Revenue and Gross Margin (2018-2023)
10.9.4 LG Life Sciences Erythropoietin (EPO) Products Offered
10.9.5 LG Life Sciences Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Erythropoietin (EPO) Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Erythropoietin (EPO) Industrial Chain Analysis
11.4 Erythropoietin (EPO) Market Dynamics
11.4.1 Erythropoietin (EPO) Industry Trends
11.4.2 Erythropoietin (EPO) Market Drivers
11.4.3 Erythropoietin (EPO) Market Challenges
11.4.4 Erythropoietin (EPO) Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Erythropoietin (EPO) Distributors
12.3 Erythropoietin (EPO) Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
